VANCOUVER, BC, June 23, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce it has received Canadian approval for its North American autism clinical study.


Previous articleCOMPASS Pathways becomes Founding Supporter of the British Neuroscience Association’s inaugural Scholars programme
Next articleBook Review: Alexander Shulgin’s The Nature of Drugs